Clinical Trial Update: Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing carfilzomib-dexamethasone to bortezomib-dexamethasone in relapsed multiple myeloma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2015-12-11